Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXOZYMES INC.EXOZ · Entity 1147 | Chief Commercial Officer | August 19, 2026 | August 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXOZYMES INC.
Report date August 19, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,499 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Exercise / conversion · Acquired 19,612 · Balance 28,499 F1: The RSU convert on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 43,147 |
Reported balance
After 2026-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-19 · Exercise / conversion · Disposed 19,612 · Balance 43,147 F1: The RSU convert on a one-for-one basis. F2: On January 14, 2026, the reporting person was granted an aggregate of 62,759 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 19,612 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU convert on a one-for-one basis.
F2: On January 14, 2026, the reporting person was granted an aggregate of 62,759 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 19,612 shares of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 25, 2026 23:16 UTC | EXOZYMES INC. EXOZ · Entity 1147 | Exercise / conversionRestricted Stock Unit · Derivative | 19,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-040129 · ownership.xml · derivative · entry 2 Perriman Damien Alan · CIK 0002096714 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,147 Underlying: Common Stock · 19,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The RSU convert on a one-for-one basis. F2 · derivative.exercise_date: On January 14, 2026, the reporting person was granted an aggregate of 62,759 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 19,612 shares of common stock. F2 · derivative.expiration_date: On January 14, 2026, the reporting person was granted an aggregate of 62,759 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 19,612 shares of common stock. Read SEC document |
| August 19, 2026 Filed Aug 25, 2026 23:16 UTC | EXOZYMES INC. EXOZ · Entity 1147 | Exercise / conversionCommon Stock | 19,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040129 · ownership.xml · nonDerivative · entry 1 Perriman Damien Alan · CIK 0002096714 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The RSU convert on a one-for-one basis. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 23:22 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantStock Option for Common Stock · Derivative | 146,437 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0001493152-26-015761 · ownership.xml · derivative · entry 2 Perriman Damien Alan · CIK 0002096714 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,437 Underlying: Common Stock · 146,437 shares Expires 2033-04-12 F2 · security: The shares underlying the stock option grant vest at a rate of 3,050 shares per month, with 36,609 shares vesting immediately. The final vesting installment consists of 3,078 shares on April 1, 2029. The grant and each exercise of the option is pursuant to Rule 16b-3 of Section 16 of the Securities and Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 23:22 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantRestricted Stock Grant for Common Stock | 62,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-015761 · ownership.xml · nonDerivative · entry 1 Perriman Damien Alan · CIK 0002096714 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,759 F1 · security: The shares underlying the grant of the restricted stock vest at a rate of 3,923 shares per quarter, with 15,689 shares vesting immediately. The final vesting installment consists of 3,917 shares on April 1, 2029. The grant and each vesting is pursuant to Rule 16b-3 of Section 16 of the Securities and Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 10:27 UTC | EXOZYMES INC. EXOZ · Entity 1147 | GrantCOMMON STOCK | 8,887 | $8.44 | $75,006.28 |
DisclosureSEC source: 0001493152-26-015630 · ownership.xml · nonDerivative · entry 1 Perriman Damien Alan · CIK 0002096714 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.